Cutaneous Lymphoma, An Issue of Dermatologic Clinics

Elise A. Olsen

Description

The Editor of this publication is Dr Elise Olsen, Director of the Duke University Cutaneous Lymphoma Research and Treatment Center and professor of Dermatology and Oncology. In 2014, cutaneous lymphoma (CL) is considered a chronic, non-life threatening disease since the majority of patients are diagnosed at early stage, though progression to later stages does result in death from the disease. This issue covers T-cell and B-cell lymphomas, with content emphasis on Mycoides fungoides and Sezary syndrome, the two most common clinically encountered subtypes of CL. Pharmaceutical treatment of the disease is a part of each article and the issue uses the following Treatment outline: Mechanisms of action - Pharmacokinetics - Typical dosing - Response to therapy - Adverse effects - and Pearls to help management using the agent under discussion. Beyond Dermatologists, specialists who would find the information useful are Cancer specialists, Hematologists/Oncologists, Physician Assistants, Nurse Practitioners, and Pharmacists. Some of the topics, written by the word's top experts in this disease, are: Overview of primary cutaneous lymphomas and the applicable staging and classification; Pathologic diagnosis of cutaneous lymphomas; in the section on Mycosis Fungoides and Sezary Syndrome, the clinician and researcher will find such topics as Skin directed medications; Phototherapy; Systemic retinoids; Interferons; HDAC inhibiotrs, Methotrexate and praletexate, along with other chemotherapeutic agents. Also, Bone marrow transplant; Diagnosis and management of CD30+ Lymphoproliferative disorders; and Diagnosis and management of primary cutaneous B cell lymphomas.

Sujets

• Médecine
• Médecine Générale
• Medical
• Dermatology

Informations

• Publié par: Elsevier
• Date de parution: 07 janvier 2016
• Nombre de lectures: 0
• EAN13: 9780323400831
• Langue: English
• Poids de l'ouvrage: 6 Mo

Extrait

Cutaneous Lymphoma
Dermatologic Clinics
Editor
Elise A. Olsen, MD, FAAD
Cutaneous Lymphoma Research and Treatment Center, Dermatopharmacology Study Center, Duke university Medical Center, Durham, NC, USA
Consulting Editor
Bruce H. Thiers

Clinics Review Articles

www.derm.theclinics.com

October 2015 Volume 33 Number 4
Table of Contents
Cover image
Title page
Copyright
Contributors
Consulting Editor
Editor
Authors
Forthcoming Issues
Forthcoming Issues
Recent Issues
Erratum
Preface. Cutaneous Lymphoma
Evaluation, Diagnosis, and Staging of Cutaneous Lymphoma
Key points
Introduction
Subtypes and epidemiology of cutaneous lymphoma
Mycosis fungoides and S zary syndrome
Non-mycosis fungoides and non-S zary syndrome cutaneous T-cell lymphomas
Cutaneous B-cell lymphomas
Summary
References
Pathologic Diagnosis of Cutaneous Lymphomas
Key points
Introduction
Cutaneous T-cell lymphomas
Cutaneous B-cell lymphomas
Summary
References
Skin-Directed Therapies in Cutaneous T-Cell Lymphoma
Key points
Introduction
Topical therapies
Topical chemotherapeutics
Retinoids
Emerging topical therapies
Summary
References
Phototherapy of Mycosis Fungoides
Key points
Introduction
Ultraviolet B phototherapy in mycosis fungoides
Psoralen plus ultraviolet A therapy in mycosis fungoides
Hand/foot psoralen plus ultraviolet A
Safety of phototherapy
Summary: practical pearls for phototherapy
References
Radiation Therapy for Cutaneous T-Cell Lymphomas
Key points
Introduction
Mycosis fungoides
Primary cutaneous anaplastic large cell lymphoma
References
The Role of Systemic Retinoids in the Treatment of Cutaneous T-Cell Lymphoma
Key points
Introduction
Retinoids and mechanism of action
Retinoids in cutaneous T-cell lymphoma
Adverse effects
Summary
References
The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma
Key points
Introduction
Interferon alfa
Interferon gamma
Interferon beta
Treatment pearls for prescribing physicians
Summary
References
Methotrexate and Pralatrexate
Key points
Introduction
Emerging concepts relevant to the optimal use of folate antagonists
Treatment
Pearls to help management using methotrexate and pralatrexate
Summary
References
Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma
Key points
Introduction
Mechanism of action of histone deacetylase inhibitors
Vorinostat (Zolinza; suberoylanilide hydroxamic acid)
Romidepsin (Istodar, depsipeptide, FK228)
Belinostat (Beleodaq; PXD101 Mechanism of action)
Panobinostat (LBH-589, Farydak)
Summary
Acknowledgments
References
Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and S zary Syndrome
Key points
Introduction
Historical aspects
Mechanism of action
Pharmacokinetics
Typical regimen
Response to therapy
Early stage mycosis fungoides
Tumor stage mycosis fungoides
Erythrodermic mycosis fungoides and S zary syndrome
Extracorporeal photopheresis and adjunctive therapies
Predictors of response
Survival
Adverse effects
Pearls to help the management of patients with mycosis fungoides/S zary syndrome being treated with extracorporeal photopheresis
Summary
References
Monoclonal Antibodies
Key points
Introduction
Antibodies currently in clinical practice
Monoclonal antibodies in clinical trials
Monoclonal antibodies with potential utility in cutaneous lymphomas
Summary
References
Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma
Key points
Introduction
Antimetabolites
Alkylating agents
Topoisomerase inhibitors
Interleukins
Purine nucleoside phosphorylase inhibitors: forodesine
Proteasome inhibitors: bortezomib
Multiagent chemotherapy
Summary
References
Hematopoietic Stem Cell Transplant for Mycosis Fungoides and S zary Syndrome
Key points
Introduction
Overview of hematopoietic stem cell transplant
Stem cell sources
Donor selection
Conditioning regimens
Complications
Graft-versus-lymphoma effect
Autologous stem cell transplant for mycosis fungoides and S zary syndrome
Allogeneic stem cell transplant for mycosis fungoides and S zary syndrome
Summary and future directions
References
Practical Management of CD30 + Lymphoproliferative Disorders
Key points
Introduction
Lymphomatoid papulosis
Primary cutaneous anaplastic large cell lymphoma
Mycosis fungoides with large cell transformation
Summary/pearls
References
Diagnosis and Management of Cutaneous B-cell Lymphoma
Key points
Introduction
Diagnosis and staging
Primary cutaneous follicle center lymphoma
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue
Primary cutaneous diffuse large B-cell lymphoma, leg type
Other B-cell lymphomas that present in skin
Treatment of the indolent cutaneous B-cell lymphomas: primary cutaneous follicle center lymphoma and mucosa-associated lymphoid tissue lymphoma
Treatment of primary cutaneous diffuse large B-cell lymphoma, leg type
Summary
References
Index
Copyright
ELSEVIER
1600 John F. Kennedy Boulevard Suite 1800 Philadelphia, Pennsylvania, 19103-2899
http://www.theclinics.com
DERMATOLOGIC CLINICS Volume 33, Number 4
October 2015 ISSN 0733-8635, ISBN-13: 978-0-323-40082-4
Editor: Jessica McCool
Developmental Editor: Alison Swety
2015 Elsevier Inc. All rights reserved.
This periodical and the individual contributions contained in it are protected under copyright by Elsevier, and the following terms and conditions apply to their use:
Photocopying
Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: ([phone] (UK)/([phone] (USA).
Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions ).
Electronic Storage or Usage
Permission of the Publisher is required to store or use electronically any material contained in this periodical, including any article or part of an article (please consult www.elsevier.com/permissions ). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.
Notice
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Dermatologic Clinics (ISSN 0733-8635) is published quarterly by Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Months of publication are January, April, July, and October. Business and editorial offices: 1600 John F. Kennedy Blvd., Suite 1800, Philadelphia, PA 19103-2899. Customer service office: 11830 Westline Drive, St. Louis, MO 63146. Periodicals postage paid at New York, NY, and additional mailing offices. Subscription prices are USD 365.00 per year for US individuals, USD 559.00 per year for US institutions, USD 425.00 per year for Canadian individuals, USD 681.00 per year for Canadian institutions, USD 495.00 per year for international individuals, USD 681.00 per year for international institutions, USD 165.00 per year for US students/residents, and USD 240.00 per year for Canadian and international students/residents. International air speed delivery is included in all Clinics subscription prices. All prices are subject to change without notice. POSTMASTER: Send address changes to Dermatologic Clinics , Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Customer Service: 1-800-654-2452 (U.S. and Canada); 314-447-8871 (outside U.S. and Canada). Fax: [phone]. E-mail: [e-mail] (for print support); [e-mail] (for online support).
Reprints. For copies of 100 or more, of articles in this publication, please contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, New York 10010-1710. Tel.: [phone]; Fax: [phone]; Email: [e-mail] .
The Dermatologic Clinics is covered in MEDLINE/PubMed (Index Medicus) , Current Contents/Clinical Medicine, Excerpta Medica, Chemical Abstracts, and ISI/BIOMED .
Printed in the United States of America.
Contributors
Consulting Editor
BRUCE H. THIERS, MD , Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, South Carolina
Editor
ELISE A. OLSEN, MD, FAAD , Professor of Dermatology and Medicine, Director, Cutane